Using a dedicated small computer in conjunction with a time-shared system in a hospital intensive care unit.

F. Farr,J. S. Clark,R. Gardner,L. Veasy

DOI: https://doi.org/10.1016/0010-4809(72)90059-6

1972-10-01

Abstract:

What problem does this paper attempt to address?

Osimertinib: Another medication related to osteonecrosis of the jaws? A case report and literature review

Feng Wang,Shengnan Wei,Zexuan Zhang,Yuan Zhang,Jingya He,Bin Sun

DOI: https://doi.org/10.3389/fphar.2022.947947

IF: 5.6

2022-08-10

Frontiers in Pharmacology

Abstract:Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is an oral complication in cancer patients being treated with either antiresorptives, mainly denosumab and bisphosphonates, or antiangiogenic drugs. Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for the treatment of patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC). TKI-induced osteonecrosis of the jaw has been reported in recent years, but these cases almost occur in combination with bisphosphonates, and the data on MRONJ associated to osimertinib is scarce. Case report: We reported a case of MRONJ associated only with osimertinib. A 69-year-old female patient with NSCLC developed MRONJ after 4 years of treatment with osimertinib. Six months ago, she felt persistent pain and swelling in the right maxilla. After 3 months of pain, her dentist extracted one tooth in the right maxilla under local anesthesia. We examined her gingiva and found fistula and pus spillage. A digital volume tomography scan revealed sequestrum. The patient underwent surgical debridement of the necrotic bone under general anesthesia and administered intravenous antibiotics at the hospital. Histopathological analysis of the bone biopsy revealed a diagnosis of MRONJ. Conclusion: This report provides evidence that osimertinib monotherapy can cause MRNOJ, and has a contribution to explore the formation mechanism of MRONJ. For those patients who take osimertinib, routine oral examinations and monitoring should be performed before and during treatment, as well as prompt closure of wounds and antibiotic treatment to avoid infection after invasive oral surgery such as tooth extraction.

pharmacology & pharmacy
Drug induced osteonecrosis of the jaw

Issam S Hamadeh,Bridget A Ngwa,Yan Gong

DOI: https://doi.org/10.1016/j.ctrv.2015.04.007

Abstract:Despite the widespread use of bisphosphonates and their unequivocal efficacy for the treatment of various disease states, osteonecrosis of the jaw remains one of the most feared complications associated with their use. Current evidence, however, suggests that there is also a relationship between occurrence of osteonecrosis of the jaw and use of other classes of pharmacotherapies namely RANKL inhibitors as well as angiogenesis inhibitors. Although these drugs have different mechanisms of action than bisphosphonates, they all seem to interfere with the bone remodeling process i.e. alter the balance between bone resorption and bone formation which may be the most plausible explanation for pathogenesis of osteonecrosis of the jaw. The main objective of this review is to introduce the readership to a number of relatively new medications that may cause osteonecrosis of the jaw. Accordingly, we will summarize latest findings from clinical studies, meta analyses and case reports published in medical literature on this topic. For some of these medications, the evidence may not appear as robust as that for bisphosphonates; yet, the possibility of this adverse event occurring with these non bisphosphonate drugs should never be precluded unless proven otherwise. Thus, it is imperative that health care providers implement preventive measures so as to circumvent the incidence of osteonecrosis of the jaw. In this day of age where medical care is becoming personalized, we will highlight some of significant findings from studies seeking to identify genetic markers that may potentially play a role in development of osteonecrosis of the jaw.
Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension?

Marta Forte,Antonio d'Amati,Luisa Limongelli,Massimo Corsalini,Gianfranco Favia,Giuseppe Ingravallo,Giuseppe Barile,Saverio Capodiferro

DOI: https://doi.org/10.3390/healthcare12040457

2024-02-11

Health Care

Abstract:Background: Medication-related osteonecrosis of the jaws is the most frequent complication in patients treated or in therapy with antiresorptive/antiangiogenetic drugs. The list of medications possibly related to MRONJ onset is constantly growing; we aimed to report on a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (Osimertinib) as possibly responsible for bilateral maxillary necrosis onset in the herein-described case. Methods: In June 2023, an oncologic patient with two different maxillary bone exposures was referred to our attention. His medical history revealed a two-year Denosumab regimen along with Osimertinib, the latter not suspended before teeth extractions. The clinicians performed a sequestrum removal and bone debridement after three cycles of antibiotic therapy. Results: Histologic examinations confirmed the clinical diagnosis of MRONJ excluding a metastatic occurrence, while complete mucosal healing was achieved after 15 days. Conclusions: The patient suspended Denosumab for more than six months before teeth extraction for MRONJ prevention; hence, failure to discontinue Osimertinib led us to consider it a possible etiological factor. From a literature analysis, only one case has already been published reporting a possible Osimertinib-related occurrence of MRONJ in lung cancer patients. Our case is a further report that could be intended as an alert both for oncologists and dentists to share decisions about the oral management of such patients together, also informing them about this possible risk. Also, this report could trigger in the scientific community the necessity to evaluate further guidelines for similar doubtful cases in which the drug interaction, the mono-suspension, and the possible removable prosthesis-related additional trauma should be considered causes or con-causes.

health care sciences & services,health policy & services
THU442 A Case Of Early Medication Related Osteonecrosis Of The Jaw In Patient Receiving Intravenous Zoledronate For Treatment Of Osteoporosis

Victor Ekpe,Xiu Ying Au,Maria Golson,Lisa E McGuire,Lina E Aguirre

DOI: https://doi.org/10.1210/jendso/bvad114.403

2023-10-01

Journal of the Endocrine Society

Abstract:Abstract Disclosure: V. Ekpe: None. X. Au: None. M. Golson: None. L.E. McGuire: None. L.E. Aguirre: None. Introduction: Medication related Osteonecrosis of the jaw (MRONJ) is a rare side effect in patients receiving nitrogen-containing bisphosphonates intravenously and other anti-bone resorptive agents such as denosumab . The incidence is 0.1% in patients with metabolic bone disease1. Annual infusions of zoledronic acid have been recommended in order to improve patient compliance, optimize therapeutic effects and to minimize side effects in selected patients. Risk factors include history of malignancy, smoking, poor dental health, prior oral surgery, high dose exposure to zoledronic acid and longer duration of treatment with anti-resorptive therapy. Increasing usage of bisphosphonates and other antiresorptive drugs, have led to an increased incidence of MRONJ. Clinical Case: We report the case of a 63-year-old Caucasian female suffering from osteoporosis who developed early stage MRONJ. She has a history of several years of oral bisphosphonate treatment and three annual administrations of zoledronic acid. Patient presented with a new complaint of gum pain and a sore above her tooth. Prior routine dental exams have all been unremarkable. She was promptly referred and evaluated by a dental provider. Dental photographs showed a resorptive defect at the gumline. Patient was diagnosed with medication related osteonecrosis of the jaw (MRONJ) in the gum area above tooth number 9. Our patient was treated with oral amoxicillin 500mg twice daily and chlorhexidine gluconate mouth rinse twice daily. The intravenous zoledronic acid was discontinued. Her gum infection resolved. Discussion: Early detection of MRONJ is possible in patients potentially at risk for this rare complication. Providers should be aware of MRONJ and refer those patients on antiresorptive drugs to the dentist for frequent evaluation and assessment for any drug-related jaw changes. References: 1. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007 Oct;22(10):1479-91. doi: 10.1359/jbmr.0707onj. PMID: 17663640. 2. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa048. doi: 10.1210/clinem/dgaa048. PMID: 32068863. Presentation: Thursday, June 15, 2023
Mechanisms Underlying Medication‐Related Osteonecrosis of the Jaw

Kyeongho Lee,Kihun Kim,June Yeon Kim,Jin‐Woo Kim,Young‐Hoon Kang,Yun Hak Kim,Sung‐Jin Kim

DOI: https://doi.org/10.1111/odi.15198

2024-11-27

Oral Diseases

Abstract:Objective Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but debilitating disease characterized by a progressive necrosis of jaw bones in patients who have received anti‐resorptive or anti‐angiogenic therapies. Unfortunately, we still have no validated preventive or pharmaceutical interventions to help these patients, primarily due to our limited understanding of MRONJ pathogenesis. Here, we offer an extensive review of recent studies relevant to MRONJ pathogenesis. We present a hypothesis regarding the coupling of bone resorption and angiogenesis that relies on osteoblast‐derived, matrix‐bound vascular endothelial growth factors to explain why ONJ is associated with both anti‐resorptive and anti‐angiogenic agents. Methods A narrative review was conducted by searching databases, including PubMed, Scopus, Google Scholar, and Web of Science, to retrieve relevant reports. Results Reduced bone resorption leads to reduced angiogenesis, and vice versa, creating a vicious cycle that ultimately results in ischemic necrosis of the jaw. Additionally, we suggest that reduced angiogenesis, induced by anti‐resorptive or anti‐angiogenic agents, aggravates bacterial infection‐induced bone necrosis, explaining why the jaw bone is particularly susceptible to necrosis. Conclusion Our novel hypothesis will facilitate the advancement of future research and the development of more targeted approaches to managing MRONJ.

dentistry, oral surgery & medicine
Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients

Bridget Boston,Deepak Ipe,Bogdan Capitanescu,Andrei Gresita,Stephen Hamlet,Robert Love,Michael Hadjiargyrou,Chien-Ling Huang,Iulian Nusem,Rodica Ileana Miroiu,Aurel Popa-Wagner,Patrick Hans-Heinrich Warnke,Eugen Bogdan Petcu

DOI: https://doi.org/10.1111/jgs.18414

Abstract:Background: Medication-related osteonecrosis of the jaw (MRONJ) is clinically defined as a non-healing jawbone ulcerative-necrotic lesion appearing after dental therapy or minor trauma in patients treated previously with anti-resorptive, anti-angiogenic or immunomodulators. Older patients with osteoporosis and cancer receive these pharmacological agents regularly. As these patients are long-term survivors, efficient treatment is of paramount importance for their quality of life. Methods: Literature searches via PubMed were conducted to identify relevant MRONJ studies. Basic information on MRONJ classification, clinical features, and pathosphysiology is presented herein as well as various clinical studies dealing with MRONJ in patients with osteoporosis and cancer. Lastly, we discuss current managment of patients and new trends in treatment of MRONJ. Results: Although close follow-up and local hygiene have been advocated by some authors, severe forms of MRONJ are not responsive to conservative therapy. At present, there is no "gold standard" therapy for this condition. However, as the physiopathological basis of MRONJ is represented by the anti-angiogenic action of various pharmacological agents, new methods to increase and promote local angiogenesis and vascularization have recently been successfully tested in vitro, limited preclinical studies, and in a pilot clinical study. Conclusions: It appears that the best method implies application on the lesion of endothelial progenitor cells as well as pro-angiogenic factors such as Vascular Endothelial Growth Factor (VEGF) and other related molecules. More recently, scaffolds in which these factors have been incorporated have shown positive results in limited trials. However, these studies must be replicated to include a large number of cases before any official therapeutic protocol is adopted.
Medication-Related Osteonecrosis Of The Jaw (Mronj): Successful Clinical Experiences In Treating Three Patients.

Ezequiel Azevedo SCHEMMFELNNIG,Eduarda Barbosa BILHALVA,Jandryce Silveira de SOUZA,Adriana ETGES,André Caroli ROCHA,Frederico SAUERESSIG,Antônio César Manentti FOGAÇA

DOI: https://doi.org/10.1016/j.oooo.2023.12.405

2024-06-07

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:We are presenting three cases of Medication-Related Osteonecrosis of the Jaw (MRONJ). Here's the information while keeping the word count constant: Case 1: A 55-year-old female with a five-year history of BetaTrinta® use presented with an oral ulcer and exposed bone in the mandibular trigone. Treatment with 0.12% chlorhexidine gel was initiated, leading to the remission of bone sequestration and tissue healing. Case 2: A 66-year-old male undergoing Denosumab® treatment for lung cancer developed necrotic bone tissue exposure and infection in the upper jaw after extractions.

dentistry, oral surgery & medicine
Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium

Guang Yang,Roy Williams,Lishu Wang,Nosha Farhadfar,Yiqing Chen,Alexander T. Loiacono,Jiang Bian,Lexie Shannon Holliday,Joseph Katz,Yan Gong

DOI: https://doi.org/10.1002/jbmr.4708

IF: 6.39

2020-01-01

Journal of Bone and Mineral Research

Abstract:Medication-related osteonecrosis of the jaw (MRONJ) is a rare but severely debilitating drug-induced bone disorder in the jawbone region. The first MRONJ was reported in 2003 after bisphosphonate (BP) exposure. Recently, other drugs, such as receptor activator of NF-kappa B ligand (RANKL) inhibitor denosumab and antiangiogenic agents, were also associated with MRONJ. The purpose of this study was to evaluate the incidence and risk factors for MRONJ related to BPs or denosumab in cancer patients in real-world clinical settings using data from the OneFlorida Clinical Research Consortium. We queried the electronic health records of participants with prescriptions of intravenous (IV) BPs or denosumab between January 1, 2012, and September 1, 2021, in the OneFlorida Consortium. Time to MRONJ diagnosis was evaluated using the Kaplan-Meier method, and Cox regression analysis was performed to estimate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for MRONJ. A total of 5689 participants had one or more prescriptions of IV BP or denosumab within this study period and were included in this study. Among these participants, 52 (0.9%) had a diagnosis of MRONJ. The overall rate of MRONJ was 0.73%, 0.86%, and 3.50% in the cancer patients treated with IV BPs, denosumab, and sequential IV BPs and denosumab, respectively. The risk of MRONJ was similar in participants treated with denosumab alone compared to those treated with IV BPs alone (HR: 1.25, 95% CI: 0.66-2.34, p = .49). Patients with sequential prescription of IV BP and denosumab were at much higher risk for MRONJ, with an adjusted HR of 4.49, 95% CI of 1.96-10.28, p = .0004. In conclusion, in real-world clinical settings, the rates of MRONJ associated with IV BPs and denosumab were similar, while the sequential treatment of these two drug classes was associated with a much higher risk of MRONJ. (c) 2022 American Society for Bone and Mineral Research (ASBMR).
Medication-Related Osteonecrosis: Why the Jawbone?

Sydney Kuehn,Rafaela Scariot,Mohammed Elsalanty

DOI: https://doi.org/10.3390/dj11050109

2023-04-24

Dentistry Journal

Abstract:Medication-related osteonecrosis of the jaw (MRONJ) has emerged as a complication of anti-resorptive medications. Despite its low incidence rate, this problem has gained attention in recent years due to its devastating consequences and lack of preventive strategy. The fact that MRONJ incidence has been exclusive to the jawbones, despite the systemic effect of anti-resorptive medications, could be a starting point to unravel the multifactorial pathogenesis of this condition. This review aims to negotiate the question of why the jawbone is more susceptible to MRONJ than other skeletal sites. Approaching the problem from this perspective could provide new directions for the prevention of MRONJ and expand our understanding of the unique oral microenvironment.
Debridement using Piezosurgical Device and Incorporation of Autologous Platelet-Rich Fibrin in Management of Stage III Medication-Related Osteonecrosis of the Jaw — A Case study and Review of Literature

Aishwarya Chatterjee,Manish Sahni,Suresh Singh,Sandeep Jain,Sandeep Jasuja,Rajgovind Sharma,Sudhir Bhandari

DOI: https://doi.org/10.1007/s12262-024-04040-x

2024-01-24

Indian Journal of Surgery

Abstract:Medication-related osteonecrosis of the jaw (MRONJ) is a condition of persistent exposure of bone or an introral/extraoral fistula through which the bone can be probed for more than 8 weeks in a patient who is under treatment with antiresorptive or antiangiogenic agents (bisphosphonates, denosumab, antiangiogenic agents, tyrosine kinase inhibitors, and monoclonal antibody targeting vascular endothelial growth factors) in the maxillofacial region without any previous history radiation therapy to the jaws or obvious metastatic disease to the jaws. High index of suspicion is required to identify this entity and treat them accordingly. We hereby present a case report where we highlighted the methods to establish the diagnosis of medication-related osteonecrosis of the jaw and its complex management from medical management to surgical management with debridement using piezosurgical device along with the incorporation of autologous platelet concentrate and review the literature of this entity.

surgery
Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series

Filipa Frutuoso,Filipe Freitas,Miguel Vilares,Helena Francisco,Duarte Marques,João Caramês,André Moreira

DOI: https://doi.org/10.3390/diseases12090205

2024-09-09

Diseases

Abstract:Medication-related osteonecrosis of the jaw (MRONJ) is a rare condition, typically seen in patients receiving antiresorptive or antiangiogenic drugs. This study aims to synthesize reports and case series of MRONJ regarding sociodemographic and clinical characteristics and to evaluate the effectiveness of the treatments applied. Following PRISMA guidelines, a search for case reports and case series was carried out in the PubMed-Medline database until March 2024. A total of 88 articles were included in this review, in a total of 151 cases. The key findings reveal that females were the most affected individuals (71% of the cases) with the average age at diagnosis being 66.27 years with a standard deviation of ±13.03. Stage 2 was the most observed stage, in 43% of cases, and zoledronic acid was the most commonly used drug (32% of cases). The oral route was the most common route of administration, in 26% of cases, with an average administration duration of 60.88 months (standard deviation ± 50.92). The mandible was the most commonly affected anatomical location (in 60% of cases). Amoxicillin + clavulanic acid (875 mg + 125 mg) and chlorhexidine (0.12%) were the most used antibiotics and mouthwash, with 16% and 26% of the cases, respectively. Surgical debridement was the most common surgical procedure, in 32% of cases, while the use of an L-PRF membrane was the most prevalent unconventional treatment, in 21% of cases. This study identified a statistically significant relationship between unconventional treatments and the cure of MRONJ (p < 0.001), indicating the need for further research to confirm these results.
Medication-Related Osteonecrosis Of The Jaw (Mronj): The Importance Of The Follow-Up.

Sara de Cassia TORNIER,Wagner Alcino Francisco Jossia GIMO,Gabriel Filipe Tosin SCIVSKI,Nayara Flores MACEDO,Amanda Britto de MACEDO,Paulo Henrique Couto SOUZA,Luciana Reis Azevedo ALANIS

DOI: https://doi.org/10.1016/j.oooo.2023.12.165

2024-06-07

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:Drug-associated osteonecrosis of the jaws is linked to antiresorptive drugs. This case report concerns a 41-year-old Caucasian female patient diagnosed with breast cancer with metastasis in the spine. The patient was referred to the Dental Clinic by the Oncology team. Upon examination, it was noted that the lower right first molar had a large coronal carious lesion causing significant pain. The treatment approach involved the extraction of the affected tooth, which was performed before the patient began using anti-resorptive medication.

dentistry, oral surgery & medicine
Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies

Aiming Jiang,Zhuoyuan Zhang,Xutong Qiu,Qiang Guo

DOI: https://doi.org/10.1007/s00204-023-03653-7

Abstract:Medication-related osteonecrosis of the jaw (MRONJ), a severe side effect caused by antiresorptive antiangiogenic medication, particularly bisphosphonates (BPs), has become a challenging disease with serious and profound effects on the physical and mental health of patients. Although it occurs with high frequency and is harmful, the exact mechanism of MRONJ remains unknown, and systematic and targeted approaches are still lacking. Maxillofacial surgeons focus on the etiology of osteonecrosis in the mandible and maxilla as well as the appropriate oral interventions for high-risk patients. Adequate nursing care and pharmacotherapy management are also crucial. This review provides a current overview of the clinicopathologic feature and research of MRONJ caused by BPs, with an emphasis on the potential mechanisms and current therapy and prevention strategies of the disease. We are of the opinion that an in-depth comprehension of the mechanisms underlying MRONJ will facilitate the development of more precise and efficacious therapeutic approaches, resulting in enhanced clinical outcomes for patients.
Medication Related Osteonecrosis of the Jaw (MRONJ) Systemic Review: Mevalonate Pathway Mechanisms Explored

Jungsuk Cho,George Feldman,Ryan Tomlinson,Dan Taub,Robert Diecidue

DOI: https://doi.org/10.1016/j.oooo.2024.05.014

2024-06-04

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but devastating condition caused by bisphosphonates, RANKL inhibitors, anti-angiogenic medications, and DMARDs. While clinical spectrum of MRONJ has a wide range, there is a subgroup of patients that do not improve with antibiotics and conservative surgical debridement resulting in pathologic fractures, draining fistulas, and/or osteomyelitis. For the severely affected individuals, the only cure is surgical resection with microvascular free flap reconstruction.

dentistry, oral surgery & medicine
Risk Factors For Medication-Related Osteonecrosis Of The Jaw In Oncological Patients.

Mariana Andrade COSTA,Victor Augusto MINARI,Adriano Tadeu Dias MARANGONI,Ana Laura Polizel Ranieri CUNHA,Lara Maria Alencar Ramos INNOCENTINI,Hilton Marcos Alves RICZ,Leandro Dorigan DE MACEDO

DOI: https://doi.org/10.1016/j.oooo.2023.12.687

2024-06-07

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:There is a lack of information regarding the risk factors for medication-related osteonecrosis of the jaw (MRONJ) in oncological patients. This retrospective observational study evaluated the clinical factors related to the risk for MRONJ occurrence in a cohort of cancer patients using zoledronic acid (ZA). Cancer patients with a history of ZA use between June 2016 and February 2019 were included. Demographic data, comorbidities, oncological and medication information, and dental history were collected.

dentistry, oral surgery & medicine
Medication-related osteonecrosis of the jaw: evolving research for multimodality medical management

Ali Abdolrahmani,Joel B. Epstein,Firoozeh Samim

DOI: https://doi.org/10.1007/s00520-024-08388-4

IF: 3.1

2024-03-06

Supportive Care in Cancer

Abstract:Medication-related osteonecrosis of the jaw (MRONJ) is a debilitating side effect of antiresorptive and antiangiogenic agents that can lead to progressive bone destruction in the maxillofacial region. Dental surgery, including tooth extractions, commonly trigger the onset of MRONJ. While guidelines suggest avoiding extraction when possible, complete avoidance is not always feasible, as necrosis can develop from dental and periodontal disease without dental procedures. The goal of this article is to provide an update review of current preventive and therapeutic approaches for MRONJ.

oncology,health care sciences & services,rehabilitation
Peri‐implant medication‐related osteonecrosis of the jaw mimicking endodontic disease in a cancer patient: A case report

André Caroli Rocha,Maria Emília Mota,Ricardo Costa Lima,Nayara Fernanda Pereira,Fabio Abreu Alves,Maria Stella Moreira

DOI: https://doi.org/10.1111/aej.12893

2024-10-14

Australian Endodontic Journal

Abstract:Medication‐related osteonecrosis of the jaw (MRONJ) is a progressive condition that can cause significant bone loss and its diagnosis can be challenging. A 68‐year‐old man with a diagnosis of hepatocellular carcinoma, undergoing treatment with atezolizumab, bevacizumab and zoledronic acid, complained of spontaneous pain in the right lower second premolar. Oral examination revealed no dental changes and implants in the right jaw. A patient history and thorough clinical and radiographic examinations mimic endodontic disease. The implant crowns were removed, bleeding on probing, and peri‐implant pockets were observed. The main hypothesis was MRONJ Stage 2, and the surgical treatment was performed. The pain ceased and signs of MRONJ were not observed within 3 months. MRONJ should be considered as a hypothesis in the case of odontalgia and a patient's history of antiresorptive and antiangiogenic therapies. Furthermore, monitoring patients with dental implants in the mandible through detailed clinical and imaging evaluation is required.

dentistry, oral surgery & medicine
Medication Related Osteonecrosis Of The Jaw (Mronj) Associated With Dental Implant Area: Report Of Advanced Bone Loss.

Natália Cristina Trentin BORDIGNON,Mariana Comparotto MINAMISAKO,Marcelo Roberto Pereira de FREITAS,Fábio Gaudenzi de FARIA,Gustavo Davi RABELO,Ricardo Luiz Cavalcanti de ALBUQUERQUE JUNIOR,Rogério GONDAK

DOI: https://doi.org/10.1016/j.oooo.2023.12.090

2024-06-07

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:Bisphosphonates (BPs) are effective antiresorptive drugs used in the treatment of cancer-related conditions, such as hypercalcemia of malignancy, spinal cord compression, and pathologic fractures due to bone metastases. They work by inhibiting bone resorption and causing apoptosis of osteoclastic cells. However, BPs have been associated with a condition known as medication-related osteonecrosis of the jaw (MRONJ). We present the case of a 71-year-old man with metastatic prostate cancer who had been treated with zoledronic acid for 32 months.

dentistry, oral surgery & medicine
Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer

Reinhard E Friedrich,Elika Madani,REINHARD E. FRIEDRICH,ELIKA MADANI

DOI: https://doi.org/10.21873/anticanres.15324

2021-09-30

Anticancer Research

Abstract:BACKGROUND: Pharmacological inhibition of osteoclast activity is an essential component of oncological therapy for patients with bone metastases. In rare cases, medication-related osteonecrosis of the jaws (MRONJ) is observed. MRONJ can cause bone defects not inferior to primary or metastatic jaw neoplasms. Oral examination of patients on osteoclast-inhibiting medication aims to identify risk factors at an early stage and to initiate therapy. The current focus on osteoclast-inhibiting drugs in the maxillofacial region is MRONJ. Effects of the substances other than MRONJ are rarely reported.CASE REPORT: The female patient with metastatic breast cancer had developed extensive osteolysis of the mandibular ramus at the time of initial diagnosis. The patient was treated with denosumab. Seven months later, a significant reduction in the mandibular osteolytic zone was recorded. However, known bone metastases from other sites had increased in size during multimodal therapy, and further metastases were recorded.CONCLUSION: Jaw metastasis can shrink under denosumab therapy.

oncology
The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies

S. Hernandez,M. Howland,T. Schiano,R. Hoffman

DOI: https://doi.org/10.3109/15563650.2015.1100305

2015-10-20

Clinical Toxicology

Abstract:Objective: Acetaminophen-induced fulminant hepatic failure is associated with acute kidney injury, metabolic acidosis, and fluid and electrolyte imbalances, requiring treatment with renal replacement therapies. Although antidote, acetylcysteine, is potentially extracted by renal replacement therapies, pharmacokinetic data are lacking to guide potential dosing alterations. We aimed to determine the extracorporeal removal of acetylcysteine by various renal replacement therapies. Methods: Simultaneous urine, plasma and effluent specimens were serially collected to measure acetylcysteine concentrations in up to three stages: before, during and upon termination of renal replacement therapy. Alterations in pharmacokinetics were determined by applying standard pharmacokinetic equations. Results: Over 2 years, 10 critically ill patients in fulminant hepatic failure requiring renal replacement therapy coincident with acetylcysteine were consecutively enrolled. All 10 patients required continuous venovenous hemofiltration (n = 10) and 2 of the 10 also required hemodialysis (n = 2). There was a significant alteration in the pharmacokinetics of acetylcysteine during hemodialysis; the area under the curve (AUC) decreased 41%, the mean extraction ratio was 51%, the mean hemodialytic clearance was 114.01 ml/kg/h, and a mean 166.75 mg/h was recovered in the effluent or 41% of the hourly dose. Alteration in the pharmacokinetics of acetylcysteine during continuous venovenous hemofiltration did not appear to be significant: the AUC decreased 13%, the mean clearance was 31.77 ml/kg/h and a mean 62.12 mg/h was recovered in the effluent or 14% of the hourly dose. Conclusions: There was no significant extraction of acetylcysteine from continuous venovenous hemofiltration. In contrast, there was significant extracorporeal removal of acetylcysteine during hemodialysis. A reasonable dose adjustment may be to double the IV infusion rate or possibly supplement with oral acetylcysteine during hemodialysis.

Using a dedicated small computer in conjunction with a time-shared system in a hospital intensive care unit.

Osimertinib: Another medication related to osteonecrosis of the jaws? A case report and literature review

Drug induced osteonecrosis of the jaw

Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension?

THU442 A Case Of Early Medication Related Osteonecrosis Of The Jaw In Patient Receiving Intravenous Zoledronate For Treatment Of Osteoporosis

Mechanisms Underlying Medication‐Related Osteonecrosis of the Jaw

Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients

Medication-Related Osteonecrosis Of The Jaw (Mronj): Successful Clinical Experiences In Treating Three Patients.

Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium

Medication-Related Osteonecrosis: Why the Jawbone?

Debridement using Piezosurgical Device and Incorporation of Autologous Platelet-Rich Fibrin in Management of Stage III Medication-Related Osteonecrosis of the Jaw — A Case study and Review of Literature

Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series

Medication-Related Osteonecrosis Of The Jaw (Mronj): The Importance Of The Follow-Up.

Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies

Medication Related Osteonecrosis of the Jaw (MRONJ) Systemic Review: Mevalonate Pathway Mechanisms Explored

Risk Factors For Medication-Related Osteonecrosis Of The Jaw In Oncological Patients.

Medication-related osteonecrosis of the jaw: evolving research for multimodality medical management

Peri‐implant medication‐related osteonecrosis of the jaw mimicking endodontic disease in a cancer patient: A case report

Medication Related Osteonecrosis Of The Jaw (Mronj) Associated With Dental Implant Area: Report Of Advanced Bone Loss.

Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer

The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies